Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied DNA Sciences, Inc. - Common Stock (NQ: APDN )

0.1771 -0.0099 (-5.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,922,181
Open 0.1800
Bid (Size) 0.1713 (2)
Ask (Size) 0.1780 (10)
Prev. Close 0.1870
Today's Range 0.1732 - 0.1933
52wk Range 0.1204 - 14.40
Shares Outstanding 10,311,885
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Via ACCESSWIRE
US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak
U.S. stock futures climbed on Wednesday as Wall Street awaits the Fed's final interest rate decision and its monetary policy forecasts for 2025. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities

Performance

YTD
-98.57%
-98.57%
1 Month
+14.26%
+14.26%
3 Month
-84.33%
-84.33%
6 Month
-62.00%
-62.00%
1 Year
-98.57%
-98.57%

More News

Read More
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
General Mills, Micron Technology And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
Via ACCESSWIRE
Looking Into Applied DNA Sciences's Recent Short Interest
Via Benzinga
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
Via ACCESSWIRE
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
Via ACCESSWIRE
Earnings Scheduled For December 17, 2024
Via Benzinga
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Via ACCESSWIRE
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
S&P 500 Edges Lower; US Crude Oil Inventories Fall
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why Applied DNA Sciences (APDN) Stock Is Down 37% Today
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Via ACCESSWIRE
Why Applied DNA Sciences (APDN) Stock Is Skyrocketing
Via Benzinga
Applied DNA Launches Mpox Clade I and Clade II Testing Service
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.